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Abstract
The receptor activator of nuclear factor-κB ligand (RANKL), its signaling receptor RANK, and 
its natural decoy receptor OPG are members of the tumour necrosis factor (TNF) and TNF 
receptor superfamily and are best known for their essential role in controlling osteoclastogen-
esis. RANKL in bone has also been shown to serve as a chemoattractant for cancer cells, thus 
explaining the tropism of certain cancers such as breast and prostate cancer to preferentially 
metastasize to bone. Here, we will discuss the important role of RANKL and its possible role in 
the management of bone loss in patients with breast cancer.
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Introduction
The receptor activator of nuclear factor-κB ligand (RANKL) is a member of the 
tumour necrosis factor (TNF) superfamily of cytokines. The protein was initially iden-
tified as a cytokine with an ability to stimulate T cell and dendritic cell function and 
was termed TRANCE, for TNF-related activation-induced cytokine, or alternatively 
as RANKL. It was cloned independently by two groups and for its ability to stimu-
late osteoclast differentiation, activity, and survival it was given the names osteoclast 
differentiation factor (ODF), and osteoprotegerin ligand (OPGL). TNF family mem-
bers mediate a panoply of biological phenomena, modulating essential aspects of 
inflammation, organogenesis, host defence, autoimmunity and apoptosis. In general, 
TNF family cytokines demonstrate pleiotropic capabilities in coordinating the devel-
opment and function of many disparate tissues and cell lineages. RANKL, in particu-
lar, assumes prominent roles in bone, the immune system, and mammary epithelium. 
The expression of both RANKL and RANK has been observed in primary breast can-
cers in humans and breast cancer cell lines, and we and others have proposed that 
the RANKL/RANK system can regulate bone metastases of epithelial tumours (Nico-
lin et al., 2008). Breast cancer frequently metastasizes to the skeleton. It is estimat-
ed that 85% of individuals with advanced disease harbour bone metastases. While 
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ductal carcinoma in situ is 98% curable if detected early, bone metastases are basically 
incurable (Jemal et al., 2007). Metastatic cancer cells tend to colonize the heavily vas-
cularized areas of the skeleton, such as the red marrow of the long bones, sternum, 
pelvis, ribs and vertebrae, where they disrupt not only bone physiology but also hae-
matopoiesis and the immune system (Mundy et al., 1999).
Discovery of osteoprotegerin, RANKL, and RANK
The receptor activator of nuclear factor-κB ligand, also called TRANCE, ODF and 
OPGL, is a type II transmembrane protein belonging to the TNF superfamily, whose 
gene was cloned fifteen years ago by four different groups contemporaneously. OPG 
was discovered independently by two groups, although the manner in which these 
groups identified it differed markedly. The Amgen group in the U.S.A. initially 
described a molecule that they had found within a project directed at characteriz-
ing cDNAs in rat intestine (Simonet et al., 1997). Mice over-expressing one particu-
lar cDNA developed marked osteopetrosis because they did not have any osteoclasts 
in their bones (Yasuda et al., 1998). The protein encoded by the gene was named 
osteoprotegerin (the bone protector), because it appeared to protect the skeleton 
from excessive bone resorption by limiting osteoclastic bone resorption (Lacey et al., 
1998, Yasuda et al., 1998a; Yasuda et al., 1998b). Independently, the Snow Brand Milk 
Group in Japan reported the identification of the identical molecule, but the route by 
which they got there was different. In 1981, Rodan et al. (1981) have proposed a nov-
el hypothesis wherein the osteoblast played a central role in mediating the hormonal 
control of osteoclastogenesis and bone resorption. Soon after, OPGL/ODF was identi-
fied as a ligand for OPG and the cellular receptor was identified as being identical 
to the previously identified RANK, which had been discovered by Anderson et al. 
(1997) at Immunex (U.S.A.) while they were sequencing cDNAs from a human bone 
marrow derived myeloid dendritic cell cDNA library. They found that RANK had 
partial homology to a portion of the extracellular domain of human CD40, a member 
of the TNF receptor superfamily, and that it was involved in the activation of T cells 
in the immune system. They then isolated RANKL by direct expression screening and 
found, like Wong et al. (1997), that it increased dendritic cell stimulated naïve T cell 
proliferation and the survival of RANK-expressing T cells. 
RANKL structure
Human RANKL is a 317-amino acid peptide that has approximately 30% homol-
ogy to the TNF-related apoptosis-inducing ligand and to CD40, and approximate-
ly 20% homology to Fas ligand (Lacey et al., 1998). It has now been shown to exist 
in two forms: a 40 to 45 kDa, membrane-bound, cellular form and a 31 kDa solu-
ble form derived by cleavage of the full- length form at position 140 or 145. RANKL 
mRNA is expressed at highest levels in bone and bone marrow, as well as in lym-
phoid tissues (lymph nodes, thymus, spleen, fetal liver and Peyer’s patches). Its 
major role in bone is the stimulation of osteoclast differentiation and activity and the 
inhibition of osteoclast apoptosis (Anderson et al, 1997). Indeed, in the presence of 
low levels of macrophage-colony stimulating factor (M-CSF), RANKL appears to be 
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both necessary and sufficient for the complete differentiation of osteoclast precursor 
cells into mature osteoclasts .
RANKL and breast cancer
Accumulating evidence has shown that RANKL is not only important for normal 
bone development, but is implicate in a spectrum of skeletal diseases characterized by 
excessive osteoclastic activity, including osteoporosis, rheumatoid arthritis and bone 
metastases. The typical tumour-induced bone lesion is focal osteolysis, although some 
tumours such as breast cancer metastases exhibit osteogenic bone lesions. The RANKL/
RANK pathway may direct breast cancer cells to preferentially migrate into bone, being 
a crucial requirement and initial step for skeletal metastasis. Epithelial cells from nor-
mal mammary glands express RANK, and RANKL-RANK signalling is required for 
the development of lactating mammary glands during pregnancy. Both RANKL- and 
RANK-deficient mice lack lactating mammary glands and cannot feed their off-spring. 
Based on high constitutive RANK expression in breast cancer specimens and cell lines, 
recent data indicate that the RANK expression status of cancer cells determines wheth-
er tumours predominantly migrate into bone, where the corresponding ligand RANKL 
is abundantly expressed. The correlation of high RANK expression with osteotropism 
in murine models was demonstrated across diverse tumour cell types, including breast 
cancer and melanoma. The osteolysis induced by these tumours affects the quality of 
life of the patients by causing pathological fractures and severe bone pain and often 
exacerbates the prognosis of the patients. Concomitantly, production of a soluble decoy 
receptor for RANKL, i.e. OPG, may be downregulated, thus eliminating one mean by 
which the ensuing osteolysis could be repressed. The imbalance in the RANKL:OPG 
ratio that results in RANKL upregulated activity leads to increased osteoclastogenesis 
and consequently bone loss (Narducci et al., 2011). The resulting vicious cycle is poten-
tially inhibited by OPG, which may lead to the development of compounds that inhibit 
the RANK/RANK-ligand pathway as therapeutic agents.
Clinical applications
As the mechanisms involved in bone metastases are further elucidated and the 
pathways involving many of the previously noted molecules are more clearly under-
stood, the clinical applications of this knowledge can have a significant impact. As 
previously mentioned, treatment for bone metastases, including surgery, radiation 
and bone-modifying agents such as bisphosphonates and denosumab, have been 
palliative in nature, attempting to slow disease progression, palliate symptoms and 
increase survival. Some of the molecules, such as RANKL, involved in metastasis-
induced bone resorption are disease-specific, but many appear to be part of a final 
common pathway that directly increases the number and activity of osteoclasts lead-
ing to bone destruction (Nicolin et al., 2008) . The development of targeted agents for 
specific molecules in this final common pathway, as evidenced by denosumab and 
the RANKL pathway, has the potential to not only palliate but also possibly prevent 
the development of bone metastases and prolong patient survival (Casas et al., 2013).
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Treatment and prevention of bone metastasis
Currently, the most promising results of targeted therapy for osseous lesions come 
from trials involving drugs that modulate the derangement of the balance in the 
RANK/RANK-ligand/OPG pathway that is a major driving force in the develop-
ment of malignant bone lesions. Following the discovery of OPG, it was thought that 
increasing OPG levels would be an effective way to inhibit the bone resorbing effects 
of RANKL. Administration of an Fc-OPG construct seems promising as a potential 
therapy in animal models of bone metastasis. Accordingly, a genetically engineered 
recombinant OPG-Fc construct (AMGN-0007) was developed as a potential therapeutic 
agent for patients with bone metastases. However, there were some concerns that pre-
vented further development of this drug in clinical trials. This agent had a short half-
life, which raised some concerns on dose scheduling for clinical use. Furthermore, OPG 
is not specific to RANKL, as it can also block TRAIL (TNF related apoptosis inducing 
ligand) which is another ligand belonging to TNF family (Emery et al., 1998). TRAIL 
is considered a very important component in natural immunity against cancer and 
is the principal mediator of tumour cell death (Nicolin et al., 2010) Thus binding of 
pharmacological doses of OPG to TRAIL may protect breast cancer cells from under-
going TRAIL-induced apoptosis (Neville et al., 2004, 2010). This may bear a potential 
risk of tumour growth with the long-term use of this drug. Therefore, as an alternative 
approach, an antibody specific to RANKL was developed which simulates the benefi-
cial effects of OPG on bone health while avoiding any potential reaction with TRAIL 
(Nicolin et al., 2010). Some epidemiologic studies suggest an anti-neoplastic role, due 
to the RANKL modulation,  of flavonoids against breast, colon, prostate cancer. Flavo-
noids are phenol compounds present in the pigments of fruit, vegetables, green tea and 
red wine. Flavonoids have two aromatic rings (ring A and ring B) linked by a bridge 
composed of three carbon atoms. Depending on their state of oxidation and function-
al groupings, flavonoids are classified in flavons, flavonons, flavonols, isoflavons, cat-
echines, anthocyanidines and calchones. The main flavonoids are quercetin (extracted 
from onion and grapes), genistein (from soya beens), apigenin (from parsley and cel-
ery), luteolin (broccoli), epicatechin, proanthocyanids, kaempferol (broccoli, grapefruit), 
catechins (green tea), resveratrol (grapes), curcumin (curcuma). The citric bioflavonoids 
include hesperidin, quercitrin, rutin and tangeritin. Although initially it was suggested 
that the biological effects might depend on their anti-oxidant activity, cell cultures stud-
ies suggest that their biological effects result from the flavonoid ability to interact with 
different molecules along the cell growth and apoptosis signalling pathways. Also the 
flavonoid metabolites retain the ability to interact with the proteins from the signalling 
pathways. The involvement of flavonoids in cell signalling might be one of the factors 
responsible for their anti-cancerous, vascular and cardio-protective activities.
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